A review of the evidence comparing the human papillomavirus vaccine versus condoms in the prevention of human papillomavirus infections

JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing

Volumn 37, Issue 3, 2008, Pages 329-337

  Miksis, Shelley ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Northwest Women's Health Care   (United States)

Author keywords

Condom; Human papillomavirus (HPV); Sexually transmitted infection; Vaccine

Indexed keywords

EID: 44649173091     PISSN: 08842175     EISSN: 15526909     Source Type: Journal    
DOI: 10.1111/j.1552-6909.2008.00236.x     Document Type: Review

References (39)

1. American Cancer Society. (2006). Cancer Facts and Figures. Atlanta, GA: Author. Retrieved August 8, 2007, from http://www.cancer.org/downloads/ STT/CAFF2006PWSecured.pdf
2. Bleeker, M., Hogewoning, C., Voorhort, F., Van Den Brule, A., Snuders, P., Starink, T., et al. (2003). Condom use promotes regression of human papillomavirus associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. International Journal of Cancer, 107, 804-810.
3. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., et al. (1995). Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. Journal of the National Cancer Institute, 87, 796-803.
4. Centers for Disease Control and Prevention. (2004a). Genital HPV infection-CDC fact sheet. Retrieved August 8, 2007, from http://www.cdc.gov/std/HPV/STDFact-HPV.htm
5. Centers for Disease Control and Prevention (2004b). Teenagers in the United States: Sexual activity, contraceptive use, and childbearing 2002. Vital Health and Statistics, 23, 1-87.
6. Centers for Disease Control and Prevention (n.d.). Fact sheet for public health personnel: Male latex condoms and sexually transmitted diseases. Retrieved August 8, 2007, from http://www.cdc.gov/nchstp/od/condoms/pdf
7. Coker, A. L., Sanders, L. C., Bond, S. M., Gerasimova, T., & Pirisi, L. (2001) Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development. Journal of Women's Health and Gender-Based Medicine, 10, 441-449.
8. Davis, K., & Weeler, S. (1999). The effectiveness of condoms in reducing heterosexual transmission of HIV. Family Planning Perspective, 31, 272-279.
9. deVilliers, E.-M., Fauquet, C., Broker, T., Bernard, H.-U., & zur Hausen, H. (2004). Classification of papillomaviruses. Virology, 324, 17-27.
10. DeVincenzi, I. (1994). A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. New England Journal of Medicine, 331, 341-346.
11. Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan, D. C., Patel, S. S., et al. (2007). Prevalence of HPV infection among females in the United States. Journal of the American Medical Association, 297, 813-819.
12. Durex Web site. (n.d.). History of condoms. Retrieved August 8, 2007, from http://www.durex/cm/condomHistory.asp?intHistoryStep= 12&intMenuOpen=4
13. Ferlay, J., Bray, F., & Pisani, P. (2004). Cancer incidence, mortality, and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon, France: IARCPress.
14. Frazer, I. H., Cox, J. T., Mayeaux, E. J., Franco, E. L., Moscicki, A.-B., Palefsky, J. M., et al. (2006). Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatric Infectious Disease Journal, 25, S65-S81.
15. Food and Drug Administration. (2006). Gardasil (quadrivalent human papillomavirus [types 6, 11, 16, 18] recombinant vaccine) [Package insert]. Whitehouse Station, NJ: Merck. Retrieved August 8, 2007, from http://www.fda.gov.offcampus.lib.washington.edu/cber/label/ HPVmer060806LB.pdf
16. The FUTURE II Study Group (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine, 356, 1915-1927.
17. Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., et al. (2007). Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine, 356, 1928-1943.
18. Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet, 364, 1757-1765.
19. Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., et al. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet, 367, 1247-1255.
20. Ho, G. Y., Bierman, R., Beradsley, L., Chang, C. J., & Burk, R. D. (1998). Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine, 338, 423-428.
21. Hogewoning, C. J., Bleeker, M. C., Van Den Brule, A. J., Voorhort, F., Snuders, P. J., Berkhof, J., et al. (2003). Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. International Journal of Cancer, 107, 811-816.
22. Holmes, K., Levine, R., & Weaver, M. (2004). Effectiveness of condoms in preventing sexually transmitted infections. Bulletin of the World Health Organization, 82, 454-461.
23. Kataja, V., Syrjanen, S. Yliskoski, M., Hippalainen, M., Vayrynen, M., Saariksoski, S., et al. (1993). Risk factors associated with cervical human papillomavirus infections: A case-control study. American Journal of Epidemiology, 138, 735-745.
24. Kjaer, S. K., de Villiers, E. M., Dahl, C., Engholm, G., Bock, J. E., Vestergaard, B. F., et al. (1991). Case-control study of risk factors for cervical neoplasia in Denmark, I: Role of the "male factor" in women with one lifetime sexual partner. International Journal of Cancer, 48, 39-44.
25. Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine, 347, 1645-1651.
26. Manhart, L. E., & Koutsky, L. A. (2002). Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sexually Transmitted Diseases, 29, 725-735.
27. Mao, C., Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Wiley, D. J., et al. (2006). Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstetrics and Gynecology, 107, 18-27.
28. Sanders, G. D., & Taira, A. V. (2003). Cost-effectiveness of a potential vaccine for human papillomavirus. Emerging Infectious Diseases, 9, 37-48.
29. Schiffman, M. (1992). Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. Journal of the National Cancer Institute, 84, 394-398.
30. Syrjanen, K., Vayrynen, M., Castren, O., Yliksoski, M., Mantyjarvi, R., Pyrhonen, S., et al. (1984). Sexual behavior of women with human papillomavirus (HPV) lesions of the uterine cervix. British Journal of Venereal Diseases, 60, 243-248.
31. Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L., Petta, C. A., Andrade, R. P., et al. (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24, 5571-5583.
32. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particles vaccine in young women: A randomized double-blinded placebo-controlled multicentre phase II efficacy trial. Lancet, 6, 271-278.
33. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., et al. (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer, 95, 1459-1466.
34. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology, 189, 12-19.
35. Wang, P. D., & Lin, R. S. (1996). Risk factors for cervical intraepithelial neoplasia in Tawain. Gynecology Oncology, 62, 10-18.
36. Weinstock, H., Berman, S., & Cates, W. (2004). Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspectives on Sexual and Reproductive Health, 36, 6-10.
37. Winer, R. L., Hughes, J. P., Feng, Q., O'Reilly, S., Kiviat, N. B., Holmes, K. K., et al. (2006). Condom use and the risk of genital human papillomavirus infection in young women. New England Journal of Medicine, 354, 2645-2656.
38. Winer, R. L., Lee, S.-K., Hughes, J., Adam D. E., Kiviat, N. B., & Koutsky, L. A. (2003). Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. American Journal of Epidemiology, 157, 218-226.
39. Zondervan, K. T., Carpenter, L. M., Painter, R., & Vessey, M. P. (1996). Oral contraceptives and cervical cancer-further findings from the Oxford Family Planning Association contraceptive study. British Journal of Cancer, 73, 1291-1297.